ClinicalTrials.gg
Active, not recruitingNCT06857955Updated Oct 23, 2026

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

A Phase 2 interventional study of Saline and QCZ484 in Hypertension, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 72 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Other

Updated Oct 23, 2026Primary completion moved1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 227 studies in Hypertension by Novartis — 4 open to participants now, 5 under way, none of them phase 3. Hypertension · Novartis.

Enrollment
95th of 222
396 · median 309
Started
2025
the only one that year
Phase 2
29 of 227
2 open now
Registered
222nd of 227
by date

Among the 227 studies in Hypertension by Novartis, this one is the 95th largest by enrollment of the 222 interventional ones that give a count, is the only one that started in 2025, is one of 29 in phase 2, and was the 222nd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

4 of the 227 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies in Hypertension by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension

Read the detailed description

Phase 2b, multicenter, randomized, double-blind, placebo-controlled, 12 months treatment study to assess the efficacy, safety, and pharmacodynamics of QCZ484 with mild to moderate hypertension (HTN). Multiple doses of QCZ484 will be tested against placebo, administered as subcutaneous injection.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • QCZ484
  • Hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Males or females aged 18 to 75 years.
  3. Diagnosis of hypertension.
  4. Hypertension treatment naive or on maximum 2 anti-HTN medications and able to undergo for 4 weeks.
  5. Mean sitting SBP ≥140 mmHg measured by OBPM and mean 24 hr SBP ≥130 mmHg and \<160 mmHg measured by ABPM.
  6. Participants able to understand and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Known history of secondary hypertension.
  2. Orthostatic hypotension.
  3. Laboratory parameter assessments outside of range at screening.
  4. Evidence of hepatic disease.
  5. Medical condition, other than hypertension, requiring treatment with RAAS inhibitor.
  6. Any history of congestive heart failure.
  7. Current or history of intolerance to ACEi and/or ARBs.
  8. cardiac arrhythmias, high-grade AV block and third-degree AV block within 6 months prior to screening.
  9. Acute myocardial infarction (AMI) or unstable angina, or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) within 12 months prior to screening. Any history of ischemic or hemorrhagic stroke or any time prior to screening.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
396 participants (actual)

Study arms

  • Placebo comparator
    Placebo Control

    Placebo

    Other: Saline

  • Experimental
    QCZ484 Dose 1

    QCZ484 Dose 1 solution for injection

    Drug: QCZ484

  • Experimental
    QCZ484 Dose 2

    QCZ484 Dose 2 solution for injection

    Drug: QCZ484

  • Experimental
    QCZ484 Dose 3

    QCZ484 Dose 3 solution for injection

    Drug: QCZ484

  • Experimental
    QCZ484 Dose 4

    QCZ484 Dose 4 solution for injection

    Drug: QCZ484

  • Experimental
    QCZ484 Dose 5

    QCZ484 Dose 5 solution for injection

    Drug: QCZ484

Interventions

  • OtherSaline

    0.9% sodium chloride saline solution

  • DrugQCZ484

    Solution of Injection

06

What researchers measure

Primary outcomes

  1. Change in Mean 24hr SBP by ABPM

    Change from baseline at Month 3 in mean 24hr systolic blood pressure (SBP) by ambulatory blood pressure measurement (ABPM)

    Time frame: Baseline, Month 3

Secondary outcomes

  1. Change in Mean 24hr SBP by ABPM

    Change from baseline at Month 6 in mean 24hr SBP by ABPM

    Time frame: Baseline, Month 6

  2. Change in SBP by OBPM

    Change from baseline at Month 3 and 6 in SBP by office blood pressure measurement (OBPM)

    Time frame: Baseline, Month 3 and 6

  3. Participants achieving SBP<130 mmHg or SBP reduced by ≥10 mmHg by ABPM

    Proportion of responders defined as participants achieving SBP\<130 mmHg or SBP reduced by ≥10 mmHg from baseline, at Month 3 and 6 by ABPM

    Time frame: Baseline, Month 3 and 6

  4. Change in DBP by ABPM and OBPM

    Change from baseline at Month 3 and 6 on diastolic blood pressure (DBP) by ABPM and OBPM

    Time frame: Baseline, Month 3 and 6

  5. Number of participants with AEs

    Number of participants with AEs by treatment group, including changes in vital signs and laboratory results qualifying and reported as AEs.

    Time frame: Up to Month 18

07

Study locations

72 sites
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Sep 2026, 17 months.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 17 months is above that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2027 → Sep 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Mar 5, 2025
StartActual
Mar 26, 2025
Primary completionActual
Sep 17, 2026was Jan 2027
CompletionEst.
Apr 5, 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 2 sites removed
Show site
  • Headlands Research Sacramento · Sacramento, United States
Show 2 removed
  • Clinical Trials Research Sacramento · Sacramento, United States
  • Trinity Health Michigan Heart · Ypsilanti, United States
Oct 23, 2026
Primary completion
Jan 29, 2027→Sep 17, 2026 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    1 site added, 2 sites removed
    Show site
    • Headlands Research Sacramento · Sacramento, United States
    Show 2 removed
    • Clinical Trials Research Sacramento · Sacramento, United States
    • Trinity Health Michigan Heart · Ypsilanti, United States
    Primary completion Jan 29, 2027→Sep 17, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06857955
Responsible party
Sponsor
First posted
Mar 5, 2025
Start date
Mar 26, 2025
Primary completion
Sep 17, 2026
Completion
Apr 5, 2028 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QCZ484

Start the discussion